文献速递细菌感染、耐药与抗菌药物医院感染防控

阳性血培养抗菌药物耐药性报告:抗菌药物耐药性领导组调查摘要

Reporting of Antimicrobial Resistance from Blood Cultures, an Antibacterial Resistance Leadership Group Survey Summary: Resistance Marker Reporting Practices from Positive Blood Cultures.
PubMed 文献 · Clin Infect Dis · 2023-01-01

抗菌药物耐药性领导组诊断委员会于2020年12月至2021年5月对美国及国外实验室开展调查,评估阳性血培养快速诊断耐药标志物的报告实践。96家实验室参与,94%已配备至少一种快速诊断,报告方法在社区与学术实验室间存在显著异质性,标准化策略亟待建立。

要点

  • 96家实验室中94%已配备至少一种阳性血培养快速诊断,方法及报告实践异质性显著。
  • 快速鉴定和耐药结果报告方式从仅列「检出/未检出」到提供解读或治疗指导注释不等。
  • 作者认为提供解读性注释与治疗指导可能有助于不熟悉耐药遗传机制的临床医生。

核心结论

  • 临床实验室对阳性血培养分子耐药检测结果的报告方式差异显著。
  • 提供解读性注释及治疗指导可能有助于不熟悉耐药遗传机制的临床医生,但并非所有实验室均如此执行。
  • 需要标准化的耐药基因结果报告策略。

研究设计与样本

  • 由抗菌药物耐药性领导组诊断委员会设计的调查,于2020年12月至2021年5月发放。
  • 调查发送至当地医院,在ClinMicroNet和Division C邮件列表共享,并纳入美国病理学家学会能力验证调查。
  • 共96家美国(95%)及美国以外(5%)不同规模实验室参与。

主要发现

  • 94%的实验室已配备至少一种快速诊断,社区实验室占52%、学术实验室占40%,服务医院规模不一。
  • 受访者共实施1至6种不同检测组合/平台,合计31种排列组合。
  • 快速鉴定和耐药结果报告方式包括将所有靶标列为「检出」/「未检出」(16-22%)而无解读指导、解读结果(23-42%)或向面向患者的医疗团队提供治疗指导注释(3-17%)。

临床怎么用

  • 作者认为,在报告结果的同时提供解读性注释与治疗指导可能有助于不熟悉耐药遗传机制的临床医生,但目前并非所有临床实验室均如此执行。
  • 作者提出需要标准化的耐药基因结果报告策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed how laboratories use and handle reporting of results of rapid diagnostics performed on positive blood culture broths, with a focus on antimicrobial resistance (AMR) markers. METHODS: A survey assembled by the Antibacterial Resistance Leadership Group Diagnostics Committee was circulated from December 2020 to May 2021. The survey was sent to local hospitals, shared on the ClinMicroNet and Division C listservs, and included in a College of American Pathologists proficiency testing survey. RESULTS: Ninety-six laboratories of various sizes across the United States (95%) and outside of the United States (5%) participated. Of the laboratories that had at least 1 rapid diagnostic in place (94%), significant heterogeneity in methods used and reporting practices was found across community (52%) and academic (40%) laboratories serving hospitals of various sizes. Respondents had implemented 1 to 6 different panels/platforms for a total of 31 permutations. Methods of reporting rapid organism identification and AMR results varied from listing all targets as "detected"/"not detected" (16-22%) without interpretive guidance, to interpreting results (23-42%), or providing therapeutic guidance comments to patient-facing healthcare teams (3-17%). CONCLUSIONS: Current approaches to reporting molecular AMR test results from positive blood culture vary significantly across clinical laboratories. Providing interpretative comments with therapeutic guidance alongside results reported may assist clinicians who are not well-versed in genetic mechanisms of AMR. However, this is currently not being done in all clinical laboratories. Standardized strategies for AMR gene result reporting are needed.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Simner PJ, Dien Bard J, Doern C, et al. Reporting of Antimicrobial Resistance from Blood Cultures, an Antibacterial Resistance Leadership Group Survey Summary: Resistance Marker Reporting Practices from Positive Blood Cultures. Clin Infect Dis. 2023. PMID: 36533704. doi:10.1093/cid/ciac952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。